These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2670432)

  • 1. Artificial cells in medical applications with emphasis on hemoperfusion in aluminium removal and cross-over control clinical trial of reduced time hemoperfusion-hemodialysis.
    Chang TM; Barre P; Lister C; Kuruvilla S
    Contrib Nephrol; 1989; 70():237-49. PubMed ID: 2670432
    [No Abstract]   [Full Text] [Related]  

  • 2. Trend evaluation of aluminium in uraemic patients on chronic hemodialysis.
    Di Iorio BR; Scarpino L; Bruno A; Confessore A; Gaudiano G; Altieri C; Smilari F; Papaleo D; Cosentino G; Terracciano V
    Nephron; 1995; 71(4):471-2. PubMed ID: 8587634
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined hemodialysis-hemoperfusion treatment reduces the time of substitutive therapy in chronic uremia.
    Stefoni S; Feliciangeli G; Coli L; Scolari MP; Bonomini V
    Int J Artif Organs; 1981 Jul; 4(4):186-91. PubMed ID: 7327760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis.
    Vasilakakis DM; D'Haese PC; Lamberts LV; Lemoniatou E; Digenis PN; De Broe ME
    Kidney Int; 1992 May; 41(5):1400-7. PubMed ID: 1614055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Determination of the plasma aluminum concentration of hemodialysis patients].
    Kuleva V; Petrov I; Antonov S; Kiriakov Z
    Vutr Boles; 1984; 23(2):51-5. PubMed ID: 6741112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routine clinical applications of hemodialysis-hemoperfusion in chronic renal failure: case reports.
    Barré PE; Gonda A; Chang TM
    Int J Artif Organs; 1986 Sep; 9(5):305-8. PubMed ID: 3023242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated removal of deferoxamine mesylate-chelated aluminum by charcoal hemoperfusion in hemodialysis patients.
    Delmez J; Weerts C; Lewis-Finch J; Windus D; Slatopolsky E
    Am J Kidney Dis; 1989 Apr; 13(4):308-11. PubMed ID: 2705449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H; Stummvoll HK; Meisinger V
    Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemoperfusion based on artificial cells for aluminium and iron removal, immunosorption, fulminant hepatic failure, uremia, poisoning and metabolic assists.
    Chang TM
    Int J Artif Organs; 1986 Sep; 9(5):285-8. PubMed ID: 3781657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative studies on the effect of hemoperfusion and hemodialysis on the elimination of some uremic toxins.
    Trznadel K; Walasek L; Kidawa Z; Lutz W
    Clin Nephrol; 1978 Dec; 10(6):229-31. PubMed ID: 729215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients.
    Klemm A; Sperschneider H; Winnefeld K; Günther K; Stein G
    Clin Nephrol; 1997 Feb; 47(2):133-4. PubMed ID: 9049466
    [No Abstract]   [Full Text] [Related]  

  • 12. Adsorption of Protein-Bound Uremic Toxins Through Direct Hemoperfusion With Hexadecyl-Immobilized Cellulose Beads in Patients Undergoing Hemodialysis.
    Yamamoto S; Sato M; Sato Y; Wakamatsu T; Takahashi Y; Iguchi A; Omori K; Suzuki Y; Ei I; Kaneko Y; Goto S; Kazama JJ; Gejyo F; Narita I
    Artif Organs; 2018 Jan; 42(1):88-93. PubMed ID: 28703401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperoxalemia in renal failure and the role of hemoperfusion and hemodialysis in primary oxalosis.
    Ahmad S; Hatch M
    Nephron; 1985; 41(3):235-40. PubMed ID: 4058624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The optimal timing of hemoperfusion component in combined hemodialysis-hemoperfusion treatment for uremic toxins removal.
    Li J; Li D; Xu Y; Wang A; Xu C; Yu C
    Ren Fail; 2015 Feb; 37(1):103-7. PubMed ID: 25421427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of hemodialysis and hemosorption on blood serum level of medium-molecular components in patients with chronic renal failure].
    Kozlov VV; Riabov SI; Dorofeeva TB; von Appen K; Spiridonov VN
    Ter Arkh; 1984; 56(7):77-81. PubMed ID: 6484840
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of blood purification on plasma levels of intact parathyroid hormone in patients with chronic renal failure.
    Liu J; Liu ZQ; Tao HQ
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Feb; 24(2):234-5. PubMed ID: 14965840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aluminum kinetics in patients treated with hemodialysis or hemofiltration with sorbent recycling of ultrafiltrate.
    Shapiro WB; Schilb TP; Porush JG
    Trans Am Soc Artif Intern Organs; 1984; 30():342-6. PubMed ID: 6533906
    [No Abstract]   [Full Text] [Related]  

  • 18. [Serum aluminum concentration and the deferoxamine test in a group of patients under chronic hemodialysis].
    de Sousa FT; Barbas JM; dos Santos JP; Mil-Homens MC; Aniceto JP; Melo JA; Rosário EM; Fonseca AP; Vizela MH
    Acta Med Port; 1986; 7(4):161-4. PubMed ID: 3825604
    [No Abstract]   [Full Text] [Related]  

  • 19. Carbamazepine clearance in hemodialysis and hemoperfusion.
    Kandrotas RJ; Oles KS; Gal P; Love JM
    DICP; 1989 Feb; 23(2):137-40. PubMed ID: 2728503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations of aluminum in hemodialysis patients.
    Sandhu G; Djebali D; Bansal A; Chan G; Smith SD
    Am J Kidney Dis; 2011 Mar; 57(3):523-5. PubMed ID: 21257246
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.